Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?

The pharmacogenomics journal - 5 Mar 2024

Cross Benjamin, Turner Richard M, Zhang J Eunice, Pirmohamed Munir

Abstract excerpt

Anticoagulants are potent therapeutics widely used in medical and surgical settings, and the amount spent on anticoagulation is rising. Although warfarin remains a widely prescribed oral anticoagulant, prescriptions of direct oral anticoagulants (DOACs) have increased rapidly. Heparin-based parenteral anticoagulants include both unfractionated and low molecular weight heparins (LMWHs). In clinical practice,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to CYP2C9 gene
Share to VKORC1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Open in PubMed Open full text

Identifiers

PMID: 38443337
DOI: 10.1038/s41397-024-00329-y
PMCID: PMC10914631

Genes

CES1
CYP2C9
CYP4F2
VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?PMID 38443337Read ↗

Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and PharmacogeneticsSemantic proximity Read ↗

PHARMACOGENOMICS OF NOVEL ORAL ANTICOAGULANTS (NOACs): CURRENT INSIGHTS AND FUTURE DIRECTIONSSemantic proximity Read ↗

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.Semantic proximity Read ↗

A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity.Semantic proximity Read ↗

Role of pharmacogenomics in the management of traditional and novel oral anticoagulants.Semantic proximity Read ↗

Should we be applying warfarin pharmacogenetics to clinical practice? No, not now.Semantic proximity Read ↗

Pharmacogenetics of Antiplatelets and Anticoagulants: A Report on Clopidogrel, Warfarin and DabigatranSemantic proximity Read ↗

Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.Semantic proximity Read ↗

Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors.Semantic proximity Read ↗

Pharmacogenetics of Novel Oral Anticoagulants: A Review of Identified Gene Variants & Future PerspectivesSemantic proximity Read ↗

Oral anticoagulation: a critique of recent advances and controversies.Semantic proximity Read ↗

A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.